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Abstract
Background
We aimed to evaluate the utility of the combined use of cardiac 123I-metaiodobenzylguani-
dine (MIBG) scintigraphy, olfactory testing, and substantia nigra (SN) hyperechogenicity on
transcranial sonography (TCS) in differentiating Parkinson’s disease (PD) from atypical
parkinsonian syndromes (APSs), such as multiple system atrophy (MSA) and progressive
supranuclear palsy (PSP).
Methods
Cardiac MIBG scintigraphy, card-type odor identification testing (Open Essence (OE),
Wako, Japan), and TCS were performed with 101 patients with PD and 38 patients with
APSs (MSA and PSP). Receiver operating characteristic (ROC) curve analysis was used
to assess the sensitivity and specificity of these batteries for diagnosing PD from APSs.
The diagnostic accuracy of the three tests was also assessed among patients at the early
disease stage (drug-naïve patients with a disease duration of 3 years or less).
Results
In differentiating PD from APSs, the area under the ROC curve was 0.74 (95% CI, 0.65–
0.83), 0.8 (95% CI, 0.73–0.87), and 0.75 (95% CI, 0.67–0.82) for TCS, cardiac MIBG scin-
tigraphy, and olfactory testing, respectively. The diagnostic sensitivity and specificity were
53.1% and 91.7%, respectively, for TCS, 70.3% and 86.8%, respectively, for cardiac MIBG
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scintigraphy, 58.4% and 76.3%, respectively, for OE. Among early-stage patients, sensitiv-
ity and specificity were 50.0% and 93.8%, respectively, for TCS, 57.1% and 87.5%, respec-
tively, for cardiac MIBG scintigraphy, and 54.8% and 79.2%, respectively, for OE. At least
one positive result from 3 tests improved sensitivity (86.1%) but decreased specificity
(63.2%). In contrast, at least 2 positive results from 3 tests had good discrimination for both
early-stage patients (50.0% sensitivity and 93.8% specificity) and patients overall (57.8%
sensitivity and 95.8% specificity). Positive results for all 3 tests yielded 100% specificity but
low sensitivity (25%).
Conclusions
At least 2 positive results from among TCS, cardiac MIBG scintigraphy, and olfactory test-
ing can support clinical diagnosis in distinguishing PD from APSs.
Introduction
Parkinson’s disease (PD) is a neurodegenerative disease that presents not only with cardinal
motor features such as bradykinesia, rigidity and resting tremor but also with numerous non-
motor signs. Despite recent advances in genetic and imaging studies, clinical diagnosis of PD
based on neurological findings remains difficult, especially during the early stage of the disease.
A clinicopathological study showed that for a disease duration of less than 5 years, only half of
patients presenting with parkinsonism received a correct diagnosis of PD [1]. In a recent sys-
tematic review, the accuracy of a clinical diagnosis of PD made by movement disorders experts
was found to be 80% [2]. Therefore, there has been increased awareness of the importance of
assessing non-motor features, such as REM sleep behavior disorder, autonomic dysfunction
and olfactory impairment, and several other clinical markers, including hyperechogenicity of
the midbrain substantia nigra (SN), all of which can manifest during the early phase of the dis-
ease or even precede disease onset [3, 4].
Olfactory impairment occurs in 90% of early-stage PD patients and often antedates the
onset of motor symptoms [5]. Thus, olfactory tests have been reported to be useful in differen-
tiating PD from other atypical parkinsonian syndromes (APSs), such as multiple system atro-
phy (MSA) and progressive supranuclear palsy (PSP) [6–8].
The usefulness of cardiac 123I-metaiodobenzylguanidine(MIBG) scintigraphy, which
assesses cardiac sympathetic nerve denervation, in distinguishing PD from APSs has been
reported. CardiacMIBG uptake is reduced in patients with PD, while its uptake is preserved in
patients with MSA or PSP [7, 9, 10]. Olfactory loss and cardiac sympathetic denervation on
MIBG scintigraphy have been included as supportive criteria in the updatedMDS diagnostic
criteria for PD [11].
In addition, hyperechogenicity of the SN on transcranial sonography (TCS) has beenmore
frequently observed in patients with PD than in those with MSA or PSP [12, 13]. Taken
together, these observations suggest that utilizing a combination of these batteries in addition
to clinical assessment would be useful to achieve a correct diagnosis of PD. Only one study that
used cardiac MIBG scintigraphy, olfactory tests and TCS showed that the combined use of
these tests was useful in differentiating patients with PD from healthy controls [14]. However,
no study has assessed the utility of the combination of these tests in distinguishing PD from
APSs. In this study, we aimed to assess the utility of the combined use of cardiac 123I-MIBG
Usefulness of Cardiac MIBG Scintigraphy, Olfactory Testing and TCS for Differentiating PD from APS
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uptake, olfactory function testing, and SN hyperechogenicity on TCS as additional diagnostic
markers in differentiating PD from APSs such as MSA and PSP.
Methods
This cross-sectional study was performed at the Department of Neurology, DokkyoMedical
University from April 2012 to March 2016. The study was approved by the institutional review
board of DokkyoMedical University Hospital and was conducted in accordance with the Dec-
laration of Helsinki. All subjects enrolled in the study provided written informed consent.
Subjects
Fig 1 shows a flowchart of patient selection.During the study period, 162 patients with parkin-
sonism were diagnosedwith PD, MSA or PSP. After patients with cognitive dysfunctionwere
excluded, 139 patients with PD-related disorders (101 PD patients, 21 MSA patients and 17
PSP patients) were included. The UK PD Society Brain Bank clinical diagnostic criteria were
used for a diagnosis of PD [15]. Also, the established criteria were used for a diagnosis of MSA
and PSP [16, 17]. Cases of secondary parkinsonism due to medication use or of parkinsonism
related to vascular lesions or trauma were excluded. A clinical diagnosis of PD or APS among
patients with parkinsonismwas made, relying on clinical assessment by expert neurologists
without knowledge of the results of TCS, olfactory testing or cardiac MIBG scintigraphy.
Patients who scored 20 or less on the Mini-Mental State Examination (MMSE) were excluded.
All the patients were followed for at least 3 years after disease onset to confirm the initial diag-
nosis. During follow-up, the clinical diagnosis of 1 patient was changed from PD to PSP, and
that of another patient was changed from PSP to PD. Among the patients with MSA, 12 had
MSA with predominant cerebellar ataxia (MSA-C), and 9 had MSA with predominant parkin-
sonism (MSA-P). Among the patients with PSP, 15 had Richardson’s syndrome, and 2 had
PSP-parkinsonism. We analyzed subgroups of early-stage PD and APS patients, which were
defined as drug-naïve patients with a disease duration of 3 years or less. For clinical assessment,
disease severity was rated using the Hoehn and Yahr (HY) stage [18]. The levodopa equivalent
dose (LED) was calculated according to previously reportedmethods [19].
Fig 1. Flowchart of patient selection and the PD diagnostic accuracy of the combined use of cardiac
MIBG scintigraphy, olfactory testing and transcranial sonography. * A total of 88 patients were
included in the analysis (51 patients were not assessable for SN echogenicity by transcranial sonography).
SN+ = substantia nigra hyperechogenicity positive; MIBG+ = cardiac MIBG scintigraphy positive; OE+ =
olfactory testing positive.
doi:10.1371/journal.pone.0165869.g001
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Transcranial sonography
TCS was performed using a conventional transcranial Doppler sonograph equipped with a 2.5
MHz transducer (LOGIQ 7; GE Healthcare, Tokyo, Japan). The midbrain was detected
through bilateral temporal windows (6–8 cm). The transducer was set over the preauricular
acoustic bone window, and the examination was carried out at a penetration depth of 14–16
cm and a dynamic range of 45–60 dB. An ultrasound unit was also used. The TCS was per-
formed by two experienced examiners, KS and AN, who were blinded to the clinical diagnosis.
The area of SN hyperechogenicity (cm2) was calculated from a frozen image that was expanded
to 3- to 4-fold magnification [20]. When bilateral hyperechogenic SN areas were observed, the
larger area was used for analysis. After patients with insufficient temporal bone windows were
excluded, a total of 88 patients (63%) were included in the SN echogenicity analysis.
Cardiac 123I-metaiodobenzylguanidine scintigraphy
The subjects were instructed to remain in a supine position for 15 minutes while 111 MBq
123I-MIBG (Fujifilm RI Pharma Co., Tokyo, Japan) was intravenously injected. Chest SPECT
and planar images were obtained using a gamma camera 15 minutes (early phase) and 4 hours
(delayed phase) after the injection. The heart-to-mediastinum(H/M) ratio was then calculated
by dividing the count density of the left ventricular region of interest (ROI) by that of the medi-
astinal ROI, as describedpreviously [21].
Olfactory function
A card-type odor identification test (Open Essence (OE), Wako, Japan) was used. The OE test
includes odorants compatible with those of the Odor Stick Identification Test for Japanese
(OSIT-J). It can be performedmore easily and more rapidly than the OSIT-J because it does
not require the application, rubbing and handling steps required for the OSIT-J [22, 23]. The
reliability of the OE test has been confirmed by its significant and strong correlation with the
average detection and recognition thresholds of olfactometry [22]. The OE includes 12 differ-
ent odors familiar to the Japanese population: India ink, wood, perfume,menthol, Japanese
orange, curry, gas for household use, rose, Hinoki cypress, sweaty socks, condensedmilk, and
roasted garlic. During the test, when the subject opens the twice-folded card, a microcapsule
breaks, and the odor is released. The subjects were asked to choose one of 6 possible answers:
correct odor, odor closest to the correct one, odor close to the correct one, odor very different
from the correct one, odor detectable but not recognizable, and no smell detected [22, 23]. A
previous study found that an OE score7 was useful for differentiating subjects with olfactory
dysfunction from healthy volunteers [22]. In this study, the optimal cut-off score for the OE
was set as 4 for differentiating PD from APS based on receiver operating characteristic curves
Statistical analyses
AMann-Whitney U-test or unpaired t-test was used, as appropriate, to compare continuous
variables. A chi-square or Fisher's exact test was used to compare categorical variables between
two groups. Based on receiver operating characteristic (ROC) curves, the sensitivity, specificity,
positive predictive value (PPV) and negative predictive value (NPV) were calculated to deter-
mine optimal cut-off points of the diagnostic tools for differentiating PD from APSs. Spearman
rank correlation coefficientswere used to assess correlations. Statistical significancewas
defined as a two-tailed p<0.05. GraphPad Prism for Windows (Version 5.01; GraphPad Soft-
ware, San Diego, USA) was used for the figures and ROC curve analyses, and IBM SPSS Statis-
tics 22.0 (IBM SPSS, Tokyo, Japan) was used for the other statistical analyses.
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Results
The clinical characteristics of the patients with PD and APSs are shown in Table 1. There were
no differences in mean age or in the distribution of the sexes between the groups. The patients
with PD had a longer disease duration than the patients with APSs, whereas the disease severity
was lower in the patients with PD than in those with APSs, according to the HY stages (2.7±0.9
vs. 3.0±0.7, p = 0.28). The percentage of de novo patients in the PD and APS groups was 50.1%
and 68.4%, respectively. The delayed H/M ratio of cardiac 123I-MIBGuptake (1.9±0.1 vs. 2.8
±0.6, p<0.001) and OE scores (3.9±2.5 vs. 6.2±2.4, p<0.001) were significantly lower in the
patients with PD compared with the patients with APSs. The SN hyperechogenic area on TCS
in the patients with PD was significantly larger than that in the patients with APSs (0.16±0.10
cm2 vs. 0.04±0.06 cm2, p<0.001). No significant differences in clinical background were
observedbetween the total cohort (n = 139) and those patients with unsuccessful recording on
TCS (n = 51) except for patient sex: the proportion of female patients was higher among
patients with unsuccessful recording on TCS than among the total cohort.
Fig 2 shows ROC curves for the TCS, cardiac MIBG scintigraphy and the olfactory function
test for PD diagnosis. The area under the ROC curve (AUC) for cardiac MIBG scintigraphy,
the olfactory function test, and SN hyperechogenic area on TCS in differentiating PD from
APSs was 0.8 (95% CI, 0.73–0.87), p<0.001; 0.75 (95% CI, 0.67–0.82), p<0.001; and 0.74 (95%
CI, 0.65–0.83), p<0.001, respectively. According to the ROC curve, we determined the optimal
cut-off point for the measure of each diagnostic tool for differentiating PD from APSs as fol-
lows: cardiac MIBG scintigraphy (delayed H/M ratio)<2.00 (sensitivity 70.3%, specificity
86.8%); OE score4 (sensitivity 58.4%, specificity 76.3%), SN hyperechogenic area on TCS
0.16 cm2 (sensitivity 53.1%, specificity 91.7%).
Table 2 illustrates the rate of positive TCS, cardiac MIBG and olfactory function test results
in the PD and APS groups with different combinations of test batteries. Among all of the
patients (Table 2A), each test had high specificity (76.3–91.7%) and high PPV (86.8–94.4%) in
differentiation. Compared with the results from each test individually (option 1; TCS, MIBG or
OE), at least one positive result among all 3 tests (option 2) improved the sensitivity of PD
diagnosis but decreased the specificity. In contrast, at least 2 positive results among the 3 tests
significantly improved the specificity and PPV of PD diagnosis (option 3; sensitivity, 59.4%;
specificity, 94.7%; PPV, 96.8%). Positive results for all 3 tests (option 4) had 100% specificity
and 100% PPV but low sensitivity (25%). In differentiating the PD group from the APS group,
the subanalysis of early-stage patients (n = 40) showed similar trends as those observed for the
total cohort for options 1–4, although in option 1, the sensitivity of a positiveMIBG result was
Table 1. Demographic and clinical data of the study participants.
PD (n = 101) APS (n = 38) (MSA 21; PSP 17) p-value
Age (years) 67.4±9.1 69.1±8.0 0.66
Sex (M/F) 47/54 14/24 0.31
Disease duration (years) 4.3±4.3 2.3±1.4 <0.001
HY stage 2.7±0.9 3.0±0.7 0.028
Cognitive function (MMSE) 27.3±2.7 26.5±2.8 0.12
LED (mg/day) 277.6±370.7 108.0±173.6 <0.001
Untreated patients, n (%) 51 (50.1) 26 (68.4) 0.058
Olfactory function (OE, Wako) 3.9±2.5 6.2±2.4 <0.001
MIBG delayed H/M ratio 1.9±0.1 2.8±0.6 <0.001
SN hyperechogenicity 0.16±0.1 0.04±0.06 <0.001
LED = levodopa equivalent dose; MIBG = 123I-metaiodobenzylguanidine, SN = substantia nigra
doi:10.1371/journal.pone.0165869.t001
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lower than that found in the analysis of all of the patients (Table 2B). As observedwith the
patients overall, among the early-stage patients, at least two positive results from 3 tests (option
3) had good discrimination (sensitivity, 50.0%; specificity, 95.8%; PPV, 95.5%).Within option
3, positive results fromOE and positive results from either TCS or cardiac MIBG scintigraphy
((TCS or MIBG) and OE) had the highest specificity and the highest PPV for both the patients
overall and the early-stage patients.
Subanalyses showed the cardiac MIBG scintigraphy, OE and TCS tests were individually
useful in differentiating the PD group from the PSP group and the PD group from the MSA
group (Table 3).
The SN hyperechogenic area on TCS was weakly negatively correlated with MMSE and OE
scores in the patients with PD but not in the patients with APSs (Table 4). In the patients with
PD, the cardiac MIBG delayed H/M ratio was significantly positively correlated with OE
(r = 0.51, p<0.001) and MMSE scores (r = 0.30, p = 0.002) and was negatively correlated with
age and disease duration (r = -0.38, p<0.001 and r = -0.26, p = 0.009, respectively). In contrast,
in the APS group, no significant correlation was observedbetween the cardiac MIBG delayed
H/M ratio and the OE score or the MMSE score. The OE score was negatively correlated with
age and positively correlated with the MMSE score in both the PD and APS groups.
Discussion
Our study is the first to show the usefulness of combining 3 different types of tests, specifically,
cardiac 123I-MIBGuptake, olfactory function (OE) and SN hyperechogenicity on TCS tests, as
Fig 2. Receiver operating characteristic curves for the TCS, cardiac MIBG scintigraphy and olfactory
function tests.
doi:10.1371/journal.pone.0165869.g002
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additional diagnosticmarkers to aid in distinguishing between PD and APS patients. At least 2
positive results from among TCS, cardiacMIBG scintigraphy, and olfactory testing can support
clinical diagnosis in distinguishing PD from APSs. Although TCS findings are not yet included
in the updatedMDS clinical diagnostic criteria for PD [11], cardiac MIBG scintigraphy, olfac-
tory function and TCS might serve as early markers for premotor and prodromal PD [24–26].
Walter et al. [27] reported that 96% of PD patients showed SN hyperechogenicity on TCS,
whereas only 9% of APS patients showed SN hyperechogenicity on TCS. Kikuchi et al. [7]
reported that the sensitivity and specificity in discriminating PD patients fromMSA patients
were 85.71% and 76.20% for cardiac MIBG scintigraphy (with a H/M ratio cut-off value of
1.795) and 73.81% and 85.71% for olfactory testing. Reduced cardiac MIBG uptake and olfac-
tory impairment assessed by the University of Pennsylvania Smell Identification Test has also
been reported to assist the differential diagnosis between vascular parkinsonism and PD [28].
In the current study, although each test had high utility individually, different combinations
of the 3 batteries performed differently in differentiating PD from APS. At least one positive
result for the olfactory function test (OE score4), cardiac MIBG scintigraphy (delayed H/M
ratio<2.00) or SN hyperechogenicity (SN hyperechogenic area0.16 cm2) showed high sensi-
tivity but low specificity for the diagnosis of PD (Table 2A and 2B, option 2). In contrast, at
least two positive results from among the 3 tests yielded good discrimination between PD and
APS in both the total cohort and early-stage patients (Table 2A and 2B, option 3), suggesting
the combined use of 2 out of 3 tests could support the clinical diagnosis of PD. Interestingly,
within option 3, positive OE results in addition to either positive MIBG results or positive SN
Table 2. Positive ratio of TCS, cardiac MIBG scintigraphy and olfactory function tests in the PD and APS groups.
A) Total patients (n = 139)
Combinations of test results PD APS p-value PD diagnosis
option Sensitivity (%) Specificity (%) PPV (%) NPV (%)
1 SN+ (0.16 cm2) 34 (53.1%) 2 (8.3%) <0.001 53.1 91.7 94.4 42.3
MIBG+ (2.0) 71 (70.3%) 5 (13.2%) <0.001 70.3 86.8 93.4 52.4
OE+ (4) 59 (58.4%) 9 (23.7%) <0.001 58.4 76.3 86.8 40.8
2 At least one positive result from 3 tests 87 (86.1%) 14 (36.8%) <0.001 86.1 63.2 86.1 63.2
3 At least two positive results from 3 tests 60 (59.4%) 2 (5.3%) <0.001 59.4 94.7 96.8 46.8
(SN or MIBG) and OE 52 (51.5%) 1 (2.6%) <0.001 51.5 97.4 98.1 43
(OE or MIBG) and SN 29 (45.3%) 1 (4.2%) <0.001 45.3 95.8 96.7 39.7
(OE or SN) and MIBG 56 (55.4%) 2 (5.3%) <0.001 55.4 94.7 96.6 44.4
4 Positive results for all 3 tests 17 (26.6%) 0 (0%) <0.001 26.6 100 100 33.8
B) Early-stage patients (n = 40)
Combinations of test results PD APS p-value PD diagnosis
option Sensitivity (%) Specificity (%) PPV (%) NPV (%)
1 SN+ (0.16 cm2) 12 (50.0%) 1 (6.3%) 0.004 50 93.8 92.3 55.6
MIBG+ (2.0) 24 (57.1%) 3 (12.5%) <0.001 57.1 87.5 88.9 53.8
OE+ (4) 23 (54.8%) 5 (20.8%) 0.007 54.8 79.2 82.1 50
2 At least one positive result from 3 tests 32 (76.2%) 8 (33.3%) 0.001 76.2 66.7 80 61.5
3 At least two positive results from 3 tests 21 (50%) 1 (4.2%) <0.001 50 95.8 95.5 52.3
(SN or MIBG) and OE 20 (47.6%) 0 (0%) <0.001 47.6 100 100 52.2
(OE or MIBG) and SN 9 (37.5%) 1 (6.3%) 0.025 37.5 93.8 90 50
(OE or SN) and MIBG 19 (45.2%) 1 (4.2%) <0.001 45.2 95.8 95 51.7
4 Positive results for all 3 tests 6 (25.0%) 0 (0%) 0.03 25 100 100 47.1
SN+ = substantia nigra hyperechogenicity positive; MIBG+ = cardiac MIBG scintigraphy positive; OE+ = olfactory testing positive
doi:10.1371/journal.pone.0165869.t002
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hyperechogenicity results provided good differentiation. Olfactory testing is easy to perform
and can detect olfactory impairment, which is present in early-stage disease without limitation,
except for patients with dementia. In contrast, cardiac MIBG scintigraphy may be particularly
valuable considering that olfactory testing can be hindered by the presence of dementia or
Table 3. Positive ratios of TCS, cardiac MIBG scintigraphy and olfactory function tests for the PD vs. PSP and PD vs. MSA groups.
(A) PD vs. PSP
Combinations of test results PD (n = 101) PSP (n = 17) p-value PD diagnosis
option Sensitivity (%) Specificity (%) PPV (%) NPV (%)
1 SN+ (0.16 cm2) 34 (53.1%) 0 (0%) 0.003 53.1 100 100 23.1
MIBG+ (2.0) 71 (70.3%) 2 (11.8%) <0.001 70.3 88.2 97.3 33.3
OE+ (4) 59 (58.4%) 5 (29.4%) 0.026 58.4 70.6 92.2 22.2
2 At least one positive result from 3 tests 87(86.1%) 7 (41.2%) <0.001 86.1 58.8 92.6 41.7
3 At least two positive results from 3 tests 60 (59.4%) 0 (0%) <0.001 59.4 100 100 29.3
(SN or MIBG) and OE 52(51.5%) 0(0%) <0.001 51.5 100 100 25.8
(OE or MIBG) and SN 29(45.3%) 0(0%) 0.009 45.3 100 100 20.5
(OE or SN) and MIBG 56(55.4%) 0(0%) <0.001 55.4 100 100 27.4
4 Positive results for all 3 tests 17(26.6%) 0(0%) 0.078 26.6 100 100 16.1
(B) PD vs. MSA
Combinations of test results PD (n = 101) MSA (n = 21) p-value PD diagnosis
option Sensitivity (%) Specificity (%) PPV (%) NPV (%)
1 SN+ (0.16 cm2) 34 (53.1%) 2 (13.3%) 0.005 53.1 86.7 94.4 30.2
MIBG+ (2.0) 71 (70.3%) 3 (14.3%) <0.001 70.3 85.7 95.9 37.5
OE+ (4) 59 (58.4%) 4 (19%) 0.001 58.4 81.0 93.7 28.8
2 At least one positive result from 3 tests 87(86.1%) 7(33.3%) <0.001 86.1 66.7 92.6 50
3 At least two positive results from 3 tests 60(59.4%) 2(9.5%) <0.001 59.4 90.5 96.8 31.7
(SN or MIBG) and OE 52(51.5%) 1(4.8%) <0.001 51.5 95.2 98.1 29.0
(OE or MIBG) and SN 29(45.3) 1(6.7%) 0.006 45.3 93.3 96.7 28.6
(OE or SN) and MIBG 56(55.4%) 2(9.5%) <0.001 55.4 90.5 96.6 29.7
4 Positive results for all 3 tests 17(26.6%) 0(0%) 0.024 26.6 100 100 24.2
SN+ = substantia nigra hyperechogenicity positive; MIBG+ = cardiac MIBG scintigraphy positive; OE+ = olfactory testing positive; PPV = positive predictive
value; NPV = negative predictive value.
doi:10.1371/journal.pone.0165869.t003
Table 4. Correlation between the TCS test, olfactory test, and cardiac MIBG scintigraphy results and
clinical parameters.
TCS (SN
hyperechogenicity)
Cardiac MIBG Olfactory testing
PD APS PD APS PD APS
Cardiac MIBG -0.056 0.13
Olfactory testing -0.26* -0.21 0.51** 0.12
Age 0.098 0.088 -0.38** -0.019 -0.24* -0.51**
MMSE -0.29* -0.097 0.30** 0.14 0.28** 0.36*
Disease duration 0.20 -0.19 -0.26** 0.37* -0.17 0.15
HY stage 0.20 -0.045 -0.19 0.24 -0.12 0.17
Spearman’s rank correlation coefficient
*p<0.05
**p<0.01
doi:10.1371/journal.pone.0165869.t004
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sinus diseases and that SN hyperechogenicity can be assessed in only a limited number of Japa-
nese patients with PD. A positive result on all 3 tests had high specificity and PPV but low sen-
sitivity for PD diagnosis (Table 2A and 2B, option 4).
In a previous study that included patients in the early stage of PD and MSA, cardiac MIBG
scintigraphy was more sensitive in differentiating PD fromMSA, while olfactory function tests
had higher specificity [7]. In our study, cardiac MIBG scintigraphy showed higher sensitivity
and specificity than the olfactory function test. Although 37% of patients could not be assessed
by TCS due to insufficient temporal bone windows, SN hyperechogenicity showed higher
specificity than cardiac MIBG scintigraphy or olfactory testing. A study of 65 PD patients con-
ducted by Kajimoto et al. [29] found that at cut-off values of 0.16 cm2 for SN hyperechogenicity
on TCS and 1.66 for cardiac MIBG scintigraphy, the rates of positive SN hyperechogenicity
and cardiac MIBG scintigraphy were 80% and 73%, respectively. The combined use of TCS
and cardiac MIBG scintigraphy showed a sensitivity of 97%. Izawa et al. [14] assessed the utility
of the combined use of TCS, cardiac MIBG scintigraphy and olfactory testing in differentiating
PD patients from healthy controls. They found that the positive results from either one or both
tests in combination with SN hyperechogenicity and olfactory tests yielded a sensitivity of
91.2% and 47.1%, respectively, whereas positive results from either one or both tests combined
with olfactory and cardiac MIBG scintigraphy tests yielded a sensitivity of 87.1% and 55.9%,
respectively. The specificity of the combination of cardiac MIBG scintigraphy with either SN
hyperechogenicity or olfactory testing was not assessed in that study. To date, the utility of
combining these testing modalities in discriminating between patients with PD and patients
with APSs has not been evaluated.
In patients with PD, olfactory impairment has been correlated with cardiac sympathetic
denervation [30, 31], even in the early stages of the disease [32]. Lee et al. [33] reported that the
degree of cardiac sympathetic dysfunction, as evaluated by cardiac MIBG scintigraphy, was
positively correlated with the degree of olfactory identification impairment in patients with PD
but not in patients with MSA. These findings are consistent with our study results and support
the concept that olfactory impairment and cardiac sympathetic denervationmight be potential
indicators for Lewy pathology [34–36]. In previous work, the area of SN hyperechogenicity was
found to be uncorrelated with cardiacMIBG scintigraphy or olfaction [14] and to remain stable
over a mean follow-up of 6.4 years [37], suggesting that this area might be a stable marker of
vulnerability in the nigrostriatal system [12]. Although SN hyperechogenicity did not predict
motor progression, impaired uptake of cardiac MIBG scintigraphy and olfactory impairment
may predict future motor and cognitive decline [38, 39]. Thus, adding SN hyperechogenicity
testing, which has a different profile from cardiac MIBG scintigraphy and olfactory
impairment, might offer additional support for the diagnosis of PD.
A limitation of this study is that patients with PSP and MSA, which are molecularly distinct
disorders (tauopathies vs. synucleinopathies), were grouped together as APS patients. Although
the subanalyses indicated that cardiac MIBG,OE and TCS tests were individually useful in dif-
ferentiating PD from PSP and PD fromMSA, these results should be confirmed by a study
with a large sample size. In addition, the group sizes for some of the subgroup analyses were
small, and a small number diagnosticmisclassifications could have significantly impacted the
overall findings. Another study limitation is that only 63% of the patients could be assessed for
SN echogenicity by TCS due to insufficient temporal bone windows. The excluded group, with
unsuccessful recording on TCS, contained a higher proportion of females than the included
group, as observed in a previous study [40]. We believe the low rate of successful SN recording
observed in this study may be due to ethnic differences betweenCaucasians and Asians. In the
review by Berg et al. [41], SN echogenicity was not detectable in 5–10% of Caucasian individu-
als and in 15–60% of Asian individuals. Kajimoto et al.’s study of SN hyperechogenicity in
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Japanese PD patients [29] showed that the SN could be adequately viewed via TCS in 46.2% of
65 PD patients. Their rate of successful SN recording was similar to ours. In our study, TCS
was performed by two experienced examiners who were blinded to the clinical diagnosis.
Although technical difficultiesmay have partially contributed to these recording failures, we
consider ethnic differences to have played a major role. Based on our study, in the case of TCS
recording failure, the combined use of olfactory testing and cardiac MIBG scintigraphy may be
a useful diagnostic tool for PD.
Dopamine transporter (DAT) scans are useful in distinguishing PD-related disorders from
drug-inducedparkinsonism, psychogenic parkinsonism, vascular parkinsonism and scans
without evidence of dopaminergic deficit [42]. In our study, DAT scan data were not included,
as DAT scanning has only recently been approved in Japan and has therefore been performed
on a limited number of patients. However, a meta-analysis found that DAT scans cannot be
used to distinguish between PD and APSs [43]. Umemura et al. [44] assessed the usefulness of
the putaminal apparent diffusion coefficient (ADC) test and cardiac MIBG scintigraphy in dif-
ferentiating PD and MSA-P patients. The results showed that both modalities were useful.
Busse et al. [45] reported that the combined assessment of motor asymmetry, hyposmia and
SN hyperechogenicity improved the diagnostic specificity for PD. Therefore, further studies of
the differentiation of PD from APSs that include the putaminal ADC test and motor asymme-
try would be interesting. In addition, our study may have included subjects with mild cognitive
impairment; such impairment could have affected the olfactory testing.
In conclusion, the sensitivity and specificity of PD diagnosis increased by combining the use
of two of three test results. Our study results confirmed the utility of the combined use of car-
diac MIBG scintigraphy, SN hyperechogenicity on TCS and olfactory testing as diagnostic
markers in distinguishing PD from APSs.
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